CN112089775A - NMN beneficial bacterium health composition and preparation method and application thereof - Google Patents

NMN beneficial bacterium health composition and preparation method and application thereof Download PDF

Info

Publication number
CN112089775A
CN112089775A CN202011191148.XA CN202011191148A CN112089775A CN 112089775 A CN112089775 A CN 112089775A CN 202011191148 A CN202011191148 A CN 202011191148A CN 112089775 A CN112089775 A CN 112089775A
Authority
CN
China
Prior art keywords
parts
nmn
lactobacillus
bifidobacterium
beneficial bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011191148.XA
Other languages
Chinese (zh)
Inventor
秦小波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Jihe Biotechnology Co ltd
Original Assignee
Chengdu Jihe Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Jihe Biotechnology Co ltd filed Critical Chengdu Jihe Biotechnology Co ltd
Priority to CN202011191148.XA priority Critical patent/CN112089775A/en
Publication of CN112089775A publication Critical patent/CN112089775A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/483—Gleditsia (locust)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/69—Polygalaceae (Milkwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the technical field of biological medicines, and discloses an NMN beneficial bacterium health composition, a preparation method and an application thereof, wherein the composition comprises the following components in parts by weight: 20-40 parts of NMN and 10-15 parts of beneficial bacterium powder0-8 parts of betaine, 0-5 parts of grape seed extract, 0-5 parts of baicalein, 0-5 parts of apigenin, 0-8 parts of astaxanthin, 0-8 parts of ginsenoside and 0-8 parts of ganoderma lucidum polysaccharide; beneficial bacteria in the NMN beneficial bacteria health composition prepared by the invention can effectively improve the micro-ecology of intestinal flora of a user, not only can improve the metabolic syndrome of the user caused by the intestinal flora, but also can improve the absorption efficiency of the intestinal tract, and is beneficial to the absorption of the NMN in the intestinal tract; the ginsenoside and the Linzhi polysaccharide GLP are mainly matched to improve the immunity of a user, so that the user is more suitable for improving NAD (nicotinamide adenine dinucleotide) after NMN enters the body+The change of the levels of various metabolic pathways caused by the level enables the organism to have stronger buffer capacity for the changes; AMPK activators (betaine, baicalein, and apigenin) act synergistically with NMN to achieve a better effect without side effects.

Description

NMN beneficial bacterium health composition and preparation method and application thereof
Technical Field
The invention relates to the technical field of biological medicines, in particular to an NMN beneficial bacterium health composition and a preparation method and application thereof.
Background
β -nicotinamide mononucleotide, english name: Beta-Nicotinamide Mononucleotide; for short: NMN; the molecular formula is as follows: c11H15N2O8P; molecular weight: 334.22. NMN is a substance originally present in the human body, has an important physiological function on human body cells, and is NAD+Synthesis of NAD in the salvage Synthesis pathway (coenzyme I)+A precursor of (a); it can be derived from various foods, including broccoli, cabbage, cucumber, green soy bean, avocado, etc., but the content is very low, and the goal of effective exogenous supplement can not be achieved. NMN is synthetic NAD in humans+By increasing NAD+Horizontal. NAD (nicotinamide adenine dinucleotide)+Nicotinamide adenine dinucleotide is called as a coenzyme in cells, is also used as a substrate of various signal reactions, and participates in thousands of biochemical reactions. In 2016, it was confirmed by Harvard university experiments that 22 month old mice (equivalent to human 60 years) returned to 6 months (equivalent to human 20 years) and prolonged 30 months after one week of NMN nicotinamide mononucleotide administration. Subsequently, NMN has been found to be helpful in maintaining telomere length, activating stem cells, activating DNA repair enzymes, repairing damaged DNA, and the like, and has been reported in the scientific, Cell, Nature, and other world Top-level academic journal.
NMN as a novel nutritional supplement can play more and more positive roles in the aspects of enhancing the vitality of the body, improving the sleep, resisting aging, promoting the health and the like of middle-aged and elderly people with weak nutritional absorption capacity, reduced physical function and low NMN synthesis level. However, as related products are brought to the market, it has been found that the absorption of NMN by the user over time is significantly reduced, possibly in relation to related carrier proteins. However, NMN mainly enters cells in a way of intestinal absorption, so it is necessary to research and develop a composition capable of protecting intestinal microecology and maintaining and activating the activity of carrier protein related to NMN absorption to ensure the absorption effect of NMN.
The beneficial bacteria mainly include lactobacillus and bifidobacterium. The lactobacillus can promote the secretion of digestive enzymes and the intestinal peristalsis, and remove intestinal garbage; the Bacillus bifidus can produce lactic acid and acetic acid after fermentation in human intestine, and has effects of increasing utilization rate of calcium, phosphorus and iron, and promoting absorption of iron and vitamin D. The bifidobacterium ferments lactose to produce galactose, which is a component forming cerebroside in the cranial nerve system and has close relation with the rapid growth of the postnatal brain of the infant. The Bifidobacterium can produce nutrients essential to human body such as vitamin B1, B2, B6, B12, alanine, valine, aspartic acid and threonine, has nutrition effect on human body, and can inhibit growth of putrefying bacteria, and reduce generation of harmful substances such as ammonia, hydrogen sulfide and noise in metabolite. Beneficial bacteria play an important role in protecting intestinal flora microecology and treating metabolic syndrome and the like of a human body, and the health of the intestinal tract and the body is the basis of NMN absorption and metabolism.
At present, the application of NMN is not scientifically expanded, and although most products related to NMN have certain effects by recommending large dose, NMN or simple combination of several nutritional supplements cannot achieve good absorption of NMN for a long time and fully exert physiological effects. Simultaneously, NMN acts on cell repair and the like, and is lack of targeting; and any possible side effects of NMN at larger doses on the human body are not clear.
Therefore, in order to improve the problems of the NMN intestinal absorption efficiency, the cell entering efficiency, the full exertion of physiological effects and the like, an NMN beneficial bacterium health composition, a preparation method and an application thereof are urgently needed.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and provides an NMN beneficial bacterium health composition, a preparation method and application thereof, which improve intestinal absorption efficiency and are beneficial to intestinal absorption of NMN.
The purpose of the invention is realized by the following technical scheme: a NMN beneficial bacteria health composition, comprising in parts by weight: 20-40 parts of NMN, 10-15 parts of beneficial bacterium powder, 0-8 parts of betaine, 0-5 parts of grape seed extract, 0-5 parts of baicalein, 0-5 parts of apigenin, 0-8 parts of astaxanthin, 0-8 parts of ginsenoside and 0-8 parts of ganoderma lucidum polysaccharide.
Preferably, the composition further comprises: 0-5 parts of anthocyanin, 0-10 parts of tryptophan, 0-10 parts of tyrosine and 0-3 parts of nicotinamide.
Preferably, the beneficial bacterium powder comprises the following components in parts by weight: 1-2 parts of bacillus subtilis, 0-10 parts of edible lactobacillus of lactobacillus order and 2-9 parts of edible bifidobacterium of bifidobacterium order.
Preferably, the edible lactobacillus of lactobacillus includes lactobacillus fermentum 0-2 parts;
preferably, the edible lactobacillus of the order lactobacillus further comprises one or more of lactobacillus acidophilus, lactobacillus casei, lactobacillus delbrueckii, lactobacillus helveticus, lactobacillus paracasei, lactobacillus plantarum, lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus gasseri, lactobacillus salivarius, lactobacillus jensenii, lactobacillus crispatus, lactobacillus brevis and lactobacillus sake;
the edible bifidobacteria of Bifidobacterium order comprise 2-3 parts of bifidobacterium lactis;
preferably, the edible bifidobacteria of the order bifidobacterium further comprises one or more of bifidobacterium breve, bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium pseudolongum, bifidobacterium thermophilum, bifidobacterium horn, bifidobacterium asteroides, bifidobacterium bovis, bifidobacterium odonta and bifidobacterium pseudocatenulatum.
Preferably, the composition further comprises at least one of the following components: 1-4 parts of pseudo-ginseng, 1-4 parts of polygala tenuifolia, 1-4 parts of schizonepeta, 2-5 parts of liquorice, 2-5 parts of rhizoma polygonati, 1-4 parts of spina gleditsiae, 1-4 parts of dendrobe, 2-5 parts of acanthopanax and 1-4 parts of tuber fleeceflower stem.
Preferably, the composition further comprises at least one of the following components: 2-3 parts of nipagin compound vinegar, 2-3 parts of fumaric acid, 2-3 parts of phosphate, 2-3 parts of xylitol, 2-3 parts of microcrystalline cellulose, 2-3 parts of sorbitan fatty acid vinegar, 2-3 parts of magnesium stearate, 2-3 parts of croscarmellose sodium, 2-3 parts of magnesium hydroxide, 2-3 parts of pregelatinized starch, 2-3 parts of calcium sulfate, 2-3 parts of fumed silica and 2-3 parts of lactose.
Preferably, the composition further comprises, in parts by weight: 0-2 parts of vitamin C and vitamin B 10 to 0.1 portion of vitamin B 20 to 0.1 portion of vitamin B 60 to 0.1 portion and vitamin B 120 to 0.0002 portion.
Preferably, the NMN beneficial bacteria health composition is in the form of granules, capsules or tablets.
Preferably, the method comprises the following steps: weighing the raw materials of the composition according to the weight ratio of the formula, mixing under clean and sterile conditions, adding low-temperature purified water for dissolving, concentrating under low-temperature conditions, dehydrating, and carrying out composite forming to obtain the NMN beneficial bacterium health composition; preferably, the temperature of the low-temperature purified water is lower than 25 ℃, and the low-temperature condition of the concentration is lower than 25 ℃.
Preferably, the NMN beneficial bacterium compound nutritional supplement comprises the NMN beneficial bacterium health composition and pharmaceutically acceptable auxiliary materials.
Preferably, the NMN beneficial bacterium compound nutritional supplement food comprises the NMN beneficial bacterium health composition and food acceptable auxiliary materials.
Preferably, the NMN beneficial bacteria health composition is applied to the preparation of nutritional supplement medicines, health-care foods or foods with special medical application.
Preferably, the nutritional supplement drug, health food or food for special medical use is a drug or food for resisting tumor, enhancing immunity, promoting cell growth and repair, preventing and treating hypertension, hyperglycemia and hyperlipidemia, preventing and treating senile degenerative diseases, controlling fat accumulation and body weight and/or preventing and treating cardiovascular diseases.
The beneficial bacteria such as the probiotics are added because the NMN mainly takes intestinal absorption as the main factor, and the beneficial bacteria can effectively improve the micro-ecology of intestinal flora of a user, not only improve the metabolic syndrome of the user caused by the intestinal flora, but also improve the intestinal absorption efficiency and facilitate the absorption in the intestinal tract of the NMN.
The ginsenoside and the Linzhi polysaccharide GLP are mainly matched to improve the immunity of a user, so that the user is more suitable for improving NAD (nicotinamide adenine dinucleotide) after NMN enters the body+The resulting changes in the levels of various metabolic pathways. The body has stronger buffer capacity to the changes.
Baicalein (Baicalein), activation mode: CAMKK; the optimal source is as follows: root of scutellaria; the method is characterized in that: the scutellaria baicalensis capsules show strong anti-tumor effect and life prolonging effect in animal experiments, and research shows that the scutellaria baicalensis capsules can reduce the content of testosterone in serum. The method is suitable for people: the composition is suitable for people with high blood pressure, high blood sugar, high blood fat, high. Not applicable to the population: it is not suitable for pregnant women and men, and has poor liver function (increasing liver burden due to long-term use).
Apigenin (Apigenin), activation mode: CAMKK; the optimal source is as follows: celery seeds; the method is characterized in that: in animal experiments, the compound shows stronger anti-tumor effect, inhibits testosterone secretion, inhibits monoamine oxidase and has good effect of reducing blood pressure. The method is suitable for people: people with high blood pressure, high blood sugar, high blood fat, high blood sugar, high. Not applicable to the population: young men and women with low androgens, those who are pregnant and women with low androgens are not suitable for many uses (in large amounts, they have adverse effects on reproductive function and are therefore not suitable for young people with fertility requirements), and those with poor liver function (long-term use increases liver burden).
Betaine (Glycine betaine), activation mode: LKB 1; the optimal source is as follows: beetroot, fructus Lycii; the method is characterized in that: the substance in human body activates AMPK, and is methyl donor, which can increase growth hormone level in vivo, compensate methyl deletion problem caused by NAM, and promote NADH to be converted into NAD+And the oxidation resistance is enhanced. The method is suitable for people: administering NAD+The precursor is matched with auxiliary materials in a full age direction, and is particularly suitable for weight-losing, sports and body-building groups. The uncomfortable group: but sugar content of beetroot is high, and diabetic patients should be cautiousEating beet root.
Astaxanthin (Astaxanthin), mode of activation: activation of AMPK by adiponectin; the optimal source is as follows: haematococcus pluvialis; the method is characterized in that: has strong antioxidation, and shows strong antitumor effect and life prolonging effect in animal experiments. The method is suitable for people: all ages are right. The uncomfortable group: none.
Resveratrol (Resveratrol), mode of activation: LKB 1/inhibit ATP synthase thereby reducing ATP; the optimal source is as follows: grape seeds/health products; the method is characterized in that: the dispute is large. The method is suitable for people: an adult. The uncomfortable group: children, sports exercisers, renal dysfunction (reduced ATP may affect motor ability and development and is therefore not suitable for adults and children with high levels of exercise, and may be taken at night if anti-aging is used).
Nicotinic acid, tryptophan, traditionally elevated NAD+Among five substances (tryptophan/Trp, nicotinic acid/NA, nicotinamide ribose/NR, nicotinamide/NAM, nicotinamide mononucleotide/NMN) of the three pathways (Press-Handler pathway, salvage synthesis pathway and salvage synthesis pathway), NMN is the most preferable scheme.
AMPK (Adenosine 5' -monophosphate (AMP) -activated protein kinase) is an AMP-dependent protein kinase, is a key molecule for the regulation of biological energy metabolism, and is the core of the study of diabetes and other metabolic-related diseases. It is expressed in various metabolism-related organs and can be activated by various stimuli of the body, including cellular stress, exercise, and substances that can affect cellular metabolism. Activation of AMPK not only can regulate biological energy metabolism (improving hypertension, hyperglycemia, hypercholesterolemia and hyperlipidemia), but also has antidepressant and neuroprotective effects (promoting mitochondrion autophagy and synthesis, reducing cerebral amyloid protein, and increasing brain-derived neurotrophic factor<BDNF>Etc.) and can activate the tumor suppressor gene pP53 and extend telomere-associated mechanisms. Also, AMPK activators may inhibit the NAD + consuming enzyme CD38 to increase NAD+Horizontal, and can promote NAMPT, which turns NAM into NMN. Exercise can also activate AMPK, which is often helpful in maintaining health and prolonging life. AMPK activators are widely present in living organisms, and different AMPK activators have different activation patterns and characteristics. CytochromesPatients with poor P450 enzyme-related genes (weak metabolizers) are not suitable to take large doses of AMPK activators (especially flavonoids), otherwise the liver is easily damaged. The AMPK activator (betaine, baicalein and apigenin) in the scheme has a better effect and no side effect by virtue of a synergistic effect with NMN.
The invention has the beneficial effects that:
beneficial bacteria in the NMN beneficial bacteria health composition prepared by the invention can effectively improve the micro-ecology of intestinal flora of a user, not only can improve the metabolic syndrome of the user caused by the intestinal flora, but also can improve the absorption efficiency of the intestinal tract, is beneficial to the absorption of NMN in the intestinal tract, and improves the efficiency of entering cells and the exertion of physiological action; the ginsenoside and the Linzhi polysaccharide GLP are mainly matched to improve the immunity of a user, so that the user is more adaptive to the NMN to improve the NAD (nicotinamide adenine dinucleotide) after entering the body+The change of the levels of various metabolic pathways caused by the level enables the organism to have stronger buffer capacity for the changes; AMPK activators (betaine, baicalein, and apigenin) act synergistically with NMN to achieve a better effect without side effects.
Drawings
Figure 1 is a statistical result of beta cell damage in different treatment groups.
Detailed Description
The technical solutions of the present invention are further described in detail below with reference to the accompanying drawings, but the scope of the present invention is not limited to the following.
Example 1
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 30 parts of NMN, 13 parts of beneficial bacterium powder, 4 parts of betaine, 3 parts of grape seed extract, 3 parts of baicalein, 3 parts of apigenin, 3 parts of astaxanthin, 4 parts of ginsenoside and 4 parts of ganoderma lucidum polysaccharide according to a ratio; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis, 2.5 parts of bifidobacterium lactis, 1.5 parts of lactobacillus fermentum, 1 part of lactobacillus acidophilus, 1 part of lactobacillus rhamnosus, 1 part of lactobacillus reuteri, 1 part of lactobacillus casei, 1 part of bifidobacterium breve and 1 part of bifidobacterium animalis;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 2
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 30 parts of NMN, 15 parts of beneficial bacterium powder, 4 parts of betaine, 3 parts of grape seed extract, 4 parts of ginsenoside, 4 parts of ganoderma lucidum polysaccharide, 6 parts of tryptophan, 6 parts of tyrosine and 3 parts of nicotinamide according to a ratio; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis, 2.5 parts of bifidobacterium lactis, 1.5 parts of lactobacillus fermentum, 1 part of lactobacillus helveticus, 1 part of lactobacillus delbrueckii, 1 part of lactobacillus paracasei, 1 part of lactobacillus plantarum, 1 part of bifidobacterium adolescentis and 1 part of bifidobacterium bifidum;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 3
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 30 parts of NMN, 10 parts of beneficial bacterium powder, 6 parts of betaine, 5 parts of grape seed extract, 3 parts of baicalein, 3 parts of apigenin, 5 parts of astaxanthin, 5 parts of tryptophan, 5 parts of tyrosine, 1.5 parts of nicotinamide, 2.5 parts of pseudo-ginseng, 2.5 parts of polygala tenuifolia, 2.5 parts of schizonepeta, 3.5 parts of liquorice, 3.5 parts of rhizoma polygonati, 2.5 parts of spina gleditsiae, 2.5 parts of dendrobe, 3.5 parts of acanthopanax and 2.5 parts of tuber fleeceflower stem according to a ratio; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis, 2.5 parts of bifidobacterium lactis, 1.5 parts of lactobacillus fermentum, 1 part of lactobacillus gasseri, 1 part of lactobacillus jensenii, 1 part of lactobacillus crispatus, 1 part of bifidobacterium infantis, 1 part of bifidobacterium pseudolongum and 1 part of bifidobacterium thermophilum;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 4
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 40 parts of NMN, 13 parts of beneficial bacterium powder, 3 parts of astaxanthin, 5 parts of ginsenoside, 5 parts of ganoderma lucidum polysaccharide, 2 parts of tryptophan, 2 parts of tyrosine and 2 parts of nicotinamide according to the proportion; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis, 2.5 parts of bifidobacterium lactis, 1.5 parts of lactobacillus fermentum, 1 part of lactobacillus acidophilus, 1 part of lactobacillus sake, 1 part of lactobacillus reuteri, 1 part of lactobacillus plantarum, 1 part of bifidobacterium horn, 1 part of bifidobacterium bovis and 1 part of bifidobacterium bifidum;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 5
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 28 parts of NMN and 13 parts of beneficial bacterium powder according to the proportion; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis, 2.5 parts of bifidobacterium lactis and 1 part of lactobacillus fermentum;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 6
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 35 parts of NMN, 10 parts of beneficial bacterium powder, 8 parts of ginsenoside, 8 parts of ganoderma lucidum polysaccharide, 8 parts of tryptophan, 8 parts of tyrosine, 1.5 parts of nicotinamide, 3 parts of pseudo-ginseng, 3 parts of polygala tenuifolia, 3 parts of schizonepeta, 4 parts of liquorice, 3 parts of rhizoma polygonati, 4 parts of spina gleditsiae, 4 parts of dendrobe, 3 parts of acanthopanax and 2 parts of tuber fleeceflower stem according to the proportion; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis, 2.5 parts of bifidobacterium lactis, 1 part of lactobacillus fermentum, 1 part of lactobacillus casei, 1 part of lactobacillus sake, 1 part of bifidobacterium breve, 1 part of bifidobacterium odonta and 1 part of bifidobacterium pseudocatenulatum;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 7
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 30 parts of NMN, 15 parts of beneficial bacterium powder, 5 parts of tryptophan, 5 parts of tyrosine and tobacco according to the proportion3 portions of amide, 1 portions of vitamin C and vitamin B10.1 portion of vitamin B20.1 portion of vitamin B60.1 part and vitamin B120.0002 part; the beneficial bacterium powder comprises the following components in parts by weight: 1 part of lactobacillus acidophilus, 2.5 parts of bifidobacterium lactis, 1.5 parts of lactobacillus fermentum, 1 part of lactobacillus plantarum and 1 part of lactobacillus reuteri;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 8
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 30 parts of NMN, 12 parts of beneficial bacterium powder, 8 parts of betaine, 5 parts of grape seed extract, 3 parts of baicalein, 3 parts of apigenin, 5 parts of astaxanthin, 5 parts of tryptophan, 5 parts of tyrosine, 1.5 parts of nicotinamide, 2 parts of pseudo-ginseng, 2 parts of radix Polygalae, 2 parts of herba Schizonepetae, 2 parts of licorice, 2 parts of rhizoma Polygonati, 2 parts of spina Gleditsiae, 4 parts of dendrobe, 2 parts of acanthopanax, 2 parts of caulis Polygoni Multiflori, vitamin C1 parts, vitamin B10.1 portion of vitamin B20.1 portion of vitamin B60.1 part and vitamin B120.0002 part; the beneficial bacterium powder comprises the following components in parts by weight: 1.5 parts of bacillus subtilis and 2.5 parts of bifidobacterium lactis;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Example 9
1) Several groups of NMN beneficial bacteria health compositions were prepared: weighing 30 parts of NMN, 4 parts of betaine, 3 parts of grape seed extract, 3 parts of baicalein, 3 parts of apigenin, 3 parts of astaxanthin, 4 parts of ginsenoside and 4 parts of ganoderma lucidum polysaccharide according to a ratio;
2) then mixing under clean and sterile conditions, adding purified water with the temperature lower than 25 ℃ for dissolving, concentrating under the temperature lower than 25 ℃, dehydrating, and carrying out composite molding to obtain the NMN beneficial bacterium health composition.
Experimental test 1
200 ginseng were randomly invited to the experiment and divided into 10 groups of 20 people each. The first group is proportionally filled and weighed into capsules according to the scheme of example 1 and the standard of 200mg of NMN monomers, and the capsules are provided for each person; the second group is filled with 200mg NMN monomer according to the scheme of example 2, and is proportionally weighed into capsules to be provided for each person; the third group is filled with 200mg NMN monomer according to the scheme of example 3, and is weighed as a capsule according to the proportion and provided for each person; the fourth group is filled with 200mg NMN monomer according to the scheme of example 4, and is weighed as a capsule in proportion and provided for each person; the fifth group is filled with 200mg NMN monomer according to the scheme of example 5, and the fifth group is weighed as a capsule and provided for each person; the sixth group is filled and weighed as capsules according to the scheme of example 6 and the standard of 200mg of NMN monomer, and the capsules are provided for each person; the seventh group is filled and weighed as a capsule according to the scheme of example 7 and the standard of 200mg of NMN monomer in proportion and provided for each person; the eighth group is filled and weighed as a capsule according to the scheme of example 8 and the standard of 200mg of NMN monomer in proportion and provided for each person; the ninth group is prepared by the scheme of example 9, and is proportionally filled and weighed into capsules according to the standard of 200mg of NMN monomers and provided for each person; the tenth group is filled with 400mg of NMN monomer and is called as a capsule, and each group is provided for comparison; all experiments were administered one dose per person per day for three weeks, and weekly surveys were performed.
The results of the experiment are shown below, where the numbers indicate the number of people who were in the "good" conclusion of the survey feedback.
In the first week:
Figure BDA0002752823570000091
in the second week:
Figure BDA0002752823570000092
in the third week:
Figure BDA0002752823570000093
Figure BDA0002752823570000101
the investigation result shows that: the overall effect tends to increase every week. The control group (tenth group) took 400mg of NMN monomer per day, and had a relatively general effect, and 2 times the amount of NMN monomer was added. The ninth group, to which no beneficial bacteria component was added, had a slightly better effect, indicating that other components than beneficial bacteria could be combined with NMN to achieve better results. The first eight groups containing beneficial bacteria obtain better effect, and the participation of the beneficial bacteria promotes the absorption and the efficacy of NMN. The first group obtains excellent effects, which shows that NMN monomers, beneficial bacteria components and other active compositions can be effectively matched, so that the effective absorption of NMN is promoted, NMN is effectively converted into nad + in vivo, and the effective regulation and control effects are exerted in a plurality of nad + related metabolic regulation and control ways in a combined manner, so that experiment participants obtain good physical improvement experience.
Test 2
NMN healthy compositions were tested for protection against alloxan-induced beta cell injury.
In the experiment, the protective effect on alloxan-induced beta cell injury is evaluated by using an NMN healthy composition, an NMN-deficient composition (example 1, NMN is deficient) or single NMN, and the experimental result shows that the NMN or the NMN-deficient composition has a protective effect on injured cells in a certain concentration range, and the NMN healthy composition has an obvious protective effect on the injured cells and has a synergistic protective effect after combined application.
(1) Experimental Material
NMN: the molecular formula is as follows: c11H15N2O8P; molecular weight: 334.22, respectively;
composition lacking NMN: the same as in example 1, but without the addition of NMN component;
the source is as follows: NMN monomer and other components are purchased from standard samples;
storage conditions are as follows: drying, keeping out of the sun, and storing at room temperature below 25 ℃;
cell line: mouse insulinoma cell commercial standard sample;
reagent: basal medium, tetramethylazoazolium salt ((MTT), dimethyl sulfoxide (DMSO), alloxan;
the experimental method adopts an MTT method for detection.
The experimental results are as follows:
the results of the experiment are shown in FIG. 1.
The MTT method detects the influence of NMN on the cell survival rate of the alloxan damaged islet beta cells. According to the experimental result, the concentration of the alloxan is 15mM, the experiment is divided into a negative control group, an alloxan damage group and an NMN (0.5, l.0,5.0, l0 mM) protection group, and the result of figure 1 shows that the survival rate of the cells is not obviously improved after the NMN protection treatment is added.
The MTT method detects the influence of the NMN-deleted composition on the cell survival rate of the alloxan damaged islet beta cells. According to the experimental result, the concentration of the alloxan is 15mM, the experiment is divided into a negative control group, an alloxan damage group and a composition (0.5, l.0,5.0, l0 mM) protection group lacking NMN, and the result shown in figure 1 shows that the survival rate of the cells can be obviously improved after the composition lacking NMN is added for protection treatment, and the survival rate of the cells is gradually increased along with the increase of the concentration of the protection group.
The MTT assay measures the effect of NMN healthy compositions on cell viability of alloxan-damaged islet beta cells. According to the experimental result, the concentration of the alloxan is 15mM, the experiment is divided into a negative control group, an alloxan damage group and an NMN health composition embodiment series according to the scheme provided by the invention, and the NMN health composition embodiment series is an NMN health composition (0.5, l.0,5.0, l0 mM) protection group series, and the result of figure 1 shows that after the NMN health composition is added for protection treatment, the effect is greatly improved, the survival rate of cells can be obviously improved, and the survival rate of the cells is gradually improved along with the increase of the concentration of the protection group.
The experimental results suggest that: the NMN health composition can obviously improve the repair and survival rate of damaged cells, has concentration-dependent effect and has obvious combined synergistic effect.
Test 3
The first, material and method:
1. material
1.1, 100 experimental animal mice are kept consistent in age, and the weight accords with the statistical difference;
1.2, NMN health composition of the invention example 1: the dosage recommended for human body is the medium dosage according to the standard of loading 200mg of NMN monomer, and if preparing a liquid medicine, the liquid medicine is dissolved by purified water. High dose (based on NMN 80 mg/kg), medium dose (based on NMN 40 mg/kg), and low dose (based on NMN 20 mg/kg) were set.
1.3, commercially available standard samples of sodium pentobarbital and melatonin.
2. Experiment for improving sleep: 100 mice, each half of male and female, were randomly divided into 5 groups, namely a blank control group, a melatonin group, and high, medium, and low dose groups of the NMN health composition liquid medicine of example 1 of the present invention, each of which was 20 mice. Respectively intragastrically administering the composition liquid medicine at high, medium and low dosages in mice per day; the mice of the blank control group are administrated with physiological saline with the same volume; feeding melatonin group mice with l mg/kg of melatonin solution by gavage; and 21d in succession. After 15min of the last administration, 60mg/kg sodium pentobarbital is intraperitoneally injected. The influence of the NMN health composition liquid medicine on the weight and the sleep time of the mouse is observed by taking the influence of the disappearance of the weight and the righting reflex of the mouse on the weight and the sleep time of the mouse as an index. Statistical processing of data analysis of variance was performed using SPSS statistical software.
As a result:
before and after the experiment, the weight of each dose group of mice has no significant difference ((P >0.05) compared with the blank control group, which indicates that the NMN health composition liquid medicine has no influence on the weight of the mice, the sleep time of the melatonin group, the blank control group and the NMN health composition liquid medicine of the high, middle and low dose groups of mice is (142.2 +/-23.5) min, (90.4 +/-24.8) min, (185.3 +/-28.2) min, (169.5 +/-27.7) min, (157.7 +/-28.5) min respectively, the sleep time of each dose group of mice is obviously prolonged compared with that of the blank control group of mice, and the sleep latency of the melatonin group, the blank control group and the NMN health composition liquid medicine of the invention is (32.8 +/-4.4) min, (34.6 +/-5.3) min, (48.5 +/-14.9) 12.5 +/-12.5) compared with each dose group of mice, (34.9 +/-11.8) min, the sleep latency of mice in each dose group has no obvious change, and has no obvious difference (P is more than 0.05) compared with a blank control group, namely the NMN health composition liquid medicine has no obvious effect on the sleep latency of sodium pentobarbital. In conclusion, the NMN health composition of the present invention can significantly prolong the sleep time induced by sodium pentobarbital in mice.
The test proves that the NMN health composition has obvious curative effects of relieving the body and mind, promoting sleep, improving sleep quality and the like, and can be applied to preparation of medicines, foods or health-care products with the function of improving sleep.
The foregoing is illustrative of the preferred embodiments of this invention, and it is to be understood that the invention is not limited to the precise form disclosed herein and that various other combinations, modifications, and environments may be resorted to, falling within the scope of the concept as disclosed herein, either as described above or as apparent to those skilled in the relevant art. And that modifications and variations may be effected by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (10)

1. An NMN beneficial bacteria health composition, comprising in parts by weight: 20-40 parts of NMN, 10-15 parts of beneficial bacterium powder, 0-8 parts of betaine, 0-5 parts of grape seed extract, 0-5 parts of baicalein, 0-5 parts of apigenin, 0-8 parts of astaxanthin, 0-8 parts of ginsenoside and 0-8 parts of ganoderma lucidum polysaccharide.
2. The NMN beneficial bacteria health composition of claim 1, further comprising: 0-5 parts of anthocyanin, 0-10 parts of tryptophan, 0-10 parts of tyrosine and 0-3 parts of nicotinamide.
3. The NMN beneficial bacteria health composition of claim 1, wherein the beneficial bacteria powder comprises, in parts by weight: 1-2 parts of bacillus subtilis, 0-10 parts of edible lactobacillus of lactobacillus order and 2-9 parts of edible bifidobacterium of bifidobacterium order.
4. The NMN beneficial bacteria health composition of claim 3, wherein the edible Lactobacillus of the order Lactobacillales comprises Lactobacillus fermentum 0-2 parts;
preferably, the edible lactobacillus of the order lactobacillus further comprises one or more of lactobacillus acidophilus, lactobacillus casei, lactobacillus delbrueckii, lactobacillus helveticus, lactobacillus paracasei, lactobacillus plantarum, lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus gasseri, lactobacillus salivarius, lactobacillus jensenii, lactobacillus crispatus, lactobacillus brevis and lactobacillus sake;
the edible bifidobacteria of Bifidobacterium order comprise 2-3 parts of bifidobacterium lactis;
preferably, the edible bifidobacteria of the order bifidobacterium further comprises one or more of bifidobacterium breve, bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium bifidum, bifidobacterium infantis, bifidobacterium pseudolongum, bifidobacterium thermophilum, bifidobacterium horn, bifidobacterium asteroides, bifidobacterium bovis, bifidobacterium odonta and bifidobacterium pseudocatenulatum.
5. The NMN beneficial bacteria health composition of claim 1, further comprising at least one of the following components: 1-4 parts of pseudo-ginseng, 1-4 parts of polygala tenuifolia, 1-4 parts of schizonepeta, 2-5 parts of liquorice, 2-5 parts of rhizoma polygonati, 1-4 parts of spina gleditsiae, 1-4 parts of dendrobe, 2-5 parts of acanthopanax and 1-4 parts of tuber fleeceflower stem.
Preferably, the composition further comprises, in parts by weight: 0-2 parts of vitamin C and vitamin B10 to 0.1 portion of vitamin B20 to 0.1 portion of vitamin B60 to 0.1 portion and vitamin B120 to 0.0002 portion.
6. The NMN beneficial bacteria health composition of any of claims 1-5, wherein the NMN beneficial bacteria health composition is in the form of granules, capsules, or tablets.
7. The method of preparing a NMN beneficial bacteria health composition according to any of claims 1-5, comprising the steps of: weighing the raw materials of the composition according to the weight ratio of the formula, mixing under clean and sterile conditions, adding low-temperature purified water for dissolving, concentrating under low-temperature conditions, dehydrating, and carrying out composite forming to obtain the NMN beneficial bacterium health composition; preferably, the temperature of the low-temperature purified water is lower than 25 ℃, and the low-temperature condition of the concentration is lower than 25 ℃.
8. A NMN beneficial bacteria compound nutritional supplement comprising the NMN beneficial bacteria health composition of any one of claims 1 to 5, and pharmaceutically acceptable excipients.
9. A NMN beneficial bacteria compound nutritional supplement food, comprising the NMN beneficial bacteria health composition of any one of claims 1 to 5, and a food acceptable excipient.
10. Use of the NMN beneficial bacteria health composition according to any of the claims 1 to 5 for the preparation of a nutritional supplement medicament, health food or food for special medical use, wherein the nutritional supplement medicament, health food or food for special medical use is a medicament or food for anti-tumor, enhancing immunity, promoting cell growth and repair, preventing and treating hypertension, hyperglycemia and hyperlipidemia, preventing and treating age-related degenerative diseases, controlling fat accumulation and body weight and/or preventing and treating cardiovascular diseases.
CN202011191148.XA 2020-10-30 2020-10-30 NMN beneficial bacterium health composition and preparation method and application thereof Pending CN112089775A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011191148.XA CN112089775A (en) 2020-10-30 2020-10-30 NMN beneficial bacterium health composition and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011191148.XA CN112089775A (en) 2020-10-30 2020-10-30 NMN beneficial bacterium health composition and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN112089775A true CN112089775A (en) 2020-12-18

Family

ID=73784979

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011191148.XA Pending CN112089775A (en) 2020-10-30 2020-10-30 NMN beneficial bacterium health composition and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN112089775A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972386A (en) * 2021-02-23 2021-06-18 成都西域从容生物科技有限公司 NMN liposome nano-particle and preparation method thereof
CN113100439A (en) * 2021-05-17 2021-07-13 时代特殊医学用途配方食品(深圳)有限公司 NMN formula product for prolonging chromosome telomere and preparation method thereof
CN113181205A (en) * 2021-04-19 2021-07-30 苏州人本药业有限公司 Pharmaceutical compositions comprising NMN and uses thereof
CN113398143A (en) * 2021-07-30 2021-09-17 黑龙江联生生物科技有限公司 Application of beta-nicotinamide mononucleotide
CN113832204A (en) * 2021-09-22 2021-12-24 杭州吾尾科技有限公司 NMN preparation method and NMN-containing dog and cat anti-aging health product formula
CN115227821A (en) * 2021-04-23 2022-10-25 四川大学 Application of SIRT1 agonist in preparation of medicines for preventing and/or treating autoimmune diseases of digestive system
WO2023276167A1 (en) * 2021-06-29 2023-01-05 株式会社常磐植物化学研究所 Sirtuin activator
WO2023000408A1 (en) * 2021-07-22 2023-01-26 成都川宇健维生物科技有限公司 COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND ROXBURGH ROSE EXTRACT, AND APPLICATION THEREOF
CN116103206A (en) * 2023-03-13 2023-05-12 北京量化健康科技有限公司 Lactobacillus murill BYU, microbial inoculum and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109045158A (en) * 2018-10-12 2018-12-21 泓博元生命科技（深圳）有限公司 A kind of composition and preparation method and application containing NMN
CN111035649A (en) * 2019-11-15 2020-04-21 臻元国际(香港)有限公司 NMN + GLP compound nutritional supplement and preparation method and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109045158A (en) * 2018-10-12 2018-12-21 泓博元生命科技（深圳）有限公司 A kind of composition and preparation method and application containing NMN
CN111035649A (en) * 2019-11-15 2020-04-21 臻元国际(香港)有限公司 NMN + GLP compound nutritional supplement and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
X.HAN ET AL.: "AMPK activation protects cells from oxidative stress-induced senescence via autophagic flux restoration and intracellular NAD+ elevation", 《AGING CELL》 *
佚名: "《https://tieba.baidu.com/p/6306761140》", 22 October 2019 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972386A (en) * 2021-02-23 2021-06-18 成都西域从容生物科技有限公司 NMN liposome nano-particle and preparation method thereof
CN113181205A (en) * 2021-04-19 2021-07-30 苏州人本药业有限公司 Pharmaceutical compositions comprising NMN and uses thereof
CN115227821A (en) * 2021-04-23 2022-10-25 四川大学 Application of SIRT1 agonist in preparation of medicines for preventing and/or treating autoimmune diseases of digestive system
CN113100439A (en) * 2021-05-17 2021-07-13 时代特殊医学用途配方食品(深圳)有限公司 NMN formula product for prolonging chromosome telomere and preparation method thereof
WO2023276167A1 (en) * 2021-06-29 2023-01-05 株式会社常磐植物化学研究所 Sirtuin activator
WO2023000408A1 (en) * 2021-07-22 2023-01-26 成都川宇健维生物科技有限公司 COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND ROXBURGH ROSE EXTRACT, AND APPLICATION THEREOF
CN113398143A (en) * 2021-07-30 2021-09-17 黑龙江联生生物科技有限公司 Application of beta-nicotinamide mononucleotide
CN113832204A (en) * 2021-09-22 2021-12-24 杭州吾尾科技有限公司 NMN preparation method and NMN-containing dog and cat anti-aging health product formula
CN116103206A (en) * 2023-03-13 2023-05-12 北京量化健康科技有限公司 Lactobacillus murill BYU, microbial inoculum and application thereof
CN116103206B (en) * 2023-03-13 2023-08-01 北京量化健康科技有限公司 Lactobacillus murill BYU, microbial inoculum and application thereof

Similar Documents

Publication Publication Date Title
CN112089775A (en) NMN beneficial bacterium health composition and preparation method and application thereof
CN105029407A (en) Medical formula food for inflammatory bowel disease
CN104187708A (en) Total-nutrient formulated food for patients with diabetes
KR20090056385A (en) Composition for alleviation of alcohol-induced hangover comprising hovenia dulcis thunberg contained ssangwhatang
CN113017092B (en) Fermentation type small molecule peptide mixed solution for regulating blood sugar and preparation method and application thereof
CN117487683A (en) Probiotic composition with effects of resisting claustration, protecting stomach, promoting digestion and removing food retention and application thereof
CN104187634A (en) Total nutrient formula food for sarcopenia
CN104996994A (en) Chronic obstructive pulmonary disease specific full nutritional formula food
CN104187632A (en) Total-nutrient formulated food eaten by patients with osteoporosis
CN112569323A (en) Composition for dispelling effects of alcohol and protecting liver and application thereof
CN104172191A (en) Total-nutrition formula food for treating atherosclerosis
CN104187645A (en) Anti-aging full-nutrition formula food
CN111955720A (en) Special postpartum lactation-promoting diet for puerpera and preparation method thereof
CN108936628A (en) A kind of specific full nutritional formulas and preparation method thereof that patients with cerebral apoplexy is edible
CN104839684A (en) Medical formula food for people with helicobacter pylori related gastritis
CN108968037A (en) Senile dementia full nutrition formula food
CN104187651A (en) High-uric-acid prevention total-nutrition formula food
CN105878554A (en) Probiotic fermented eight-component decoction composition and preparation method and application thereof
CN104839679A (en) Medical formula food for people with heart disease
CN104996992A (en) Medical formula food for muscle attenuation syndromes
CN104187637A (en) Full-nutritional formula food for tonifying Yang
CN105029400A (en) Medical formula food for rheumatoid arthritis
CN104146254A (en) Full-nutrition formulated food for hypertension
CN108936607A (en) Chronic Obstructive Pulmonary Disease full nutrition formula food
CN104187741A (en) Total nutrient formula food for heart disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination